COVID-19, the BC-CfE Response

Objectives:

  • An update on BC-CfE’s position regarding the COVID-19 pandemic
  • An overview of the COVID-19 pandemic, clinical presentations and prevention
  • Information on what the BC-CfE is doing to facilitate access to ART in view of the COVID-19 pandemic

SPEAKERS:
Dr. Julio Montaner
Executive Director & Physician-in-Chief
BC Centre for Excellence in HIV/AIDS

Dr. Peter Phillips
Clinical Professor
Division of Infectious Diseases, University of British Columbia

Dr. Zabrina Brumme
Laboratory Director
BC Centre for Excellence in HIV/AIDS

Junine Toy, Pharm D
Senior Manager, BC-CfE Drug Treatment Program
Clinical Pharmacy Specialist, St. Paul’s Hospital


Cost: Free registration.

Click to Register

The recorded session will be accessible on the BC-CfE’s website at education.cfenet.ubc.ca/webinars.


Event Details

Days
Hours
Minutes
Seconds
Start Date
End Date
Event Category
Attendees of the BC-CfE Learning Series will be able to:
  • Summarize and describe epidemiological, behavioural, virological, and other related research relevant to the management of people living with HIV and other syndemic conditions
  • Describe and demonstrate up-to-date information regarding the care of people living with HIV and syndemic conditions (including viral hepatitis and substance use) particularly in regards to primary care, antiretroviral therapy and other treatments, and comorbid conditions
  • Review new and emerging issues in the context of the management of people living with HIV and other syndemic conditions
  • Identify both clinical and community resources to support the care of people living with HIV and syndemic conditions.
Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below